engleski

Real life experience with golimumab in Croatia

Background: Golimumab (GLM) is a human monoclonal antibody indicated in the treatment of adults with active RA, PsA and AS who have had an inadequate response to conventional therapies. Th ere are some data that persistence with GLM in immune-mediated rheumatic disease may be higher than with other TNF-α agents and may be lower in biologic-experienced compared with biologic-naive patients. Effi cacy of golimumab through 3 and 5 years of treatment in patients with RA, PsA and AS was consistent with other TNF-α antagonist. Objectives: Th e aim of this study was to evaluate the effi cacy and the retention of golimumab (GLM) in treating patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in a real-world setting.Methods: Th is was a retrospective cohort study on patients with RA (11), PsA (20) and AS (23) who had active disease despite prior treatment with c DMARDs, NSAIDs s or biological drugs. Effi cacy of GLM was evaluated at weeks 12, 36 and 52 aft er starting GLM treatment. Golimumab drug retention rate at 2 and 5 years of treatment was determined for all patients and additionally for each indication (RA, PsA, AS) and according to TNFα naivety. Statistical signifi cance was determined at the level of 0.05. Kaplan-Meier analysis was used to assess drug retention. Results: GLM demonstrated signifi cant effi cacy in terms of decreasing disease activity in RA, PsA and AS patients already at week 12. Th e results were held even at week 36 and 52. Overall 2 and 5 years retention rate was 77% and 60%, the highest being in AS patients – 90% in 2 and 5 years. Two-year retention rate for GLM in PsA and RA patients was 75% and 55%. Five-year retention rate for GLM in PsA and RA patients was 57% and 37%. TNFα naïve patients had higher retention rate in comparison to non-naïve patients (66% vs 34%). Conclusions: In this retrospective study in a real-life setting it was demonstrated that GLM is an eff ective drug for RA, PsA and AS patients with a high retention rate. GLM retention rate was higher in AS patients compared to RA and PsA patients and in TNFα naïve patients compared to patients previously treated with TNFα inhibitors.

golimumab ; rheumatoid arthritis ; ankylosing spondylitis ; psoriatic arthritis ; experience

nije evidentirano